In Reply We would like to thank Kalita and Misra for their response. They suggest that the use of an active comparator may negate the difference in adverse events of amitriptyline. However, we found that more than 30% of participants in both groups had moderate and/or severe symptoms at baseline, similar to the adverse events associated with psychotropic medications, and that the proportion with these symptoms did not increase, with no difference between groups at 6 months. Moreover, 12% of participants withdrew from our trial due to adverse events, which is similar to the number reported by other trials.1,2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Urquhart DM, Wluka A, Cicuttini F. Low-Dose Amitriptyline for Chronic Low Back Pain—Reply. JAMA Intern Med. 2019;179(3):450–451. doi:10.1001/jamainternmed.2018.8145
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: